Navigation Links
Aethlon Medical Note: Marc Robins Joins the Aethlon Team
Date:4/25/2012

SAN DIEGO, April 25, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.

(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

Aethlon Medical was originally formed to advance a medical device technology that targeted the removal of harmful metals from circulation.  At the time, our strategy to treat infectious disease was a mere seed of thought and we certainly didn't envision the opportunities that would emerge in cancer and sepsis.  Since those early days, Marc Robins has witnessed both the setbacks and advances in our quest to create innovative therapies to combat life-threatening conditions.

I am pleased to advise you that Marc has agreed to work with us to expand the awareness of our endeavors within the financial and medical community.  Additionally, he will provide our shareholders with an additional channel of communication.  Marc's unique understanding of medical technology (including the medical devices in our therapeutic pipeline) and the financial markets will help to ensure our message is properly communicated.  He is also a passionate AEMD shareholder with 35 years of experience in discovering and investing in micro-cap medical technology organizations.  Marc was a "Special Situation" columnist at FORBES magazine, the founding publisher of the The Red Chip Review, an analyst at E.F. Hutton, and a principal at The Robins Group, LLC, an institutional investment banking firm that once managed a financing that helped us advance clinical programs. Marc can be reached at (877) 276-2467 or by email at mr@aethlonmedical.com.

About Aethlon Medical

The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.

Contacts:

James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

John P. Salvador
Director, Communications
858.459.7800 x307
jps@aethlonmedical.com


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
2. Aethlon Medical Reports Immediate and Rapid Virologic Responses in Hepatitis C (HCV) Patients Receiving Hemopurifier® Treatment Protocol
3. Aethlon Medical Establishes Sepsis & Inflammation Scientific Advisory Board
4. Aethlon Medical Discloses Availability of the Biotech Showcase™ 2012 Presentation
5. Aethlon Medical Announces Biotech Showcase™ 2012 Presentation
6. Aethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes
7. Aethlon Medical Releases Shareholder Letter
8. Aethlon Medical to Present at IN3 Medical Innovation Summit on October 27th
9. Aethlon Medical Announces Availability of its Exosome Detection Assay to the Research Community
10. Aethlon Medical Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation at Exosomes and Microvesicles 2011
11. "A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression" Released by Aethlon Medical, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2020)... ... 01, 2020 , ... Dr. Michele S. Green, board-certified Anti-Aging ... Haute Beauty network. , The Haute Beauty Network, well known for its exclusivity, ... Expert. , Haute Beauty offers a prominent collective of leading doctors nationwide. The ...
(Date:3/30/2020)... , ... March 30, 2020 , ... ... its employees, today announced it has launched a series of survey question packs ... gather actionable feedback to inform mission-critical decisions. As the current situation continues to ...
(Date:3/30/2020)... ... March 30, 2020 , ... ... now offers telemedicine appointments in addition to in-person visits. The San ... safety and well-being of patients, health care professionals, and the community at large ...
Breaking Medicine Technology:
(Date:4/5/2020)... ... April 05, 2020 , ... In ... help our healthcare industry. Nufabrx®, a proprietary biomaterial company that seamlessly embeds active ... and Manufacturing Solutions Center, has shifted production for a new line of reusable ...
(Date:4/2/2020)... ... April 02, 2020 , ... FDA CDS Software Regulation:, ... 7, 2020, 1:30-3:00 p.m. EDT, https://www.fdanews.com/cdssoftwareregulation , *NEW: ... guide clinical management of the Coronavirus.* , Is one’s software regulated as a ...
(Date:4/2/2020)... ... , ... The Northern Virginia Community College Educational Foundation (NOVA Foundation) is proud ... Palm Beach, Florida. Ms. Howe is adding to her existing endowed scholarship fund ... important than ever given the current pandemic. Ms. Howe has also generously donated to ...
(Date:4/2/2020)... ... 2020 , ... Representatives fighting for children born exposed ... and guardians, to file a proof of claim in order to qualify to ... available by Purdue as part of its bankruptcy settlement. , “The COVID-19 national ...
(Date:4/1/2020)... , ... April 02, 2020 , ... Medical Device Change ... EDT, https://www.fdanews.com/mdchangemanagement , What change management method should one be using ... is often dependent on the type of change. Is it due to post-market design ...
Breaking Medicine News(10 mins):